Background: Since the introduction of 5-HT3 antagonists, delayed and anticipatory emesis becomes more apparent. It is unclear whether delayed emesis may be better controlled by continued treatment with 5-HT3 antagonists or by a change of medication to benzamides. Patients and Method: 70 patients with histologically proven ovarian carcinoma undergoing their first PEC chemotherapy (cisplatinum, epirubicin, cyclophosphamide) received 8 mg of ondansetron intravenously on the day of chemotherapy. On the next day, randomly half of the patients received ondansetron orally (2×8 mg), the other half received alizapride (3 × 100 mg) for the next 3 days. Well-being was investigated with the ‘Gießener Beschwerdebogen’ (questionnaire of complaints), combined with objective data on emesis, nausea, and bowel movement. Results: Significant differences (U test by Mann and Whitney; Kruskal-Wallis analysis) between both groups with respect to the degree of complaint were detected between the items headache, retching and loss of appetite in favour of the group receiving alizapride. A positive trend with respect to tiredness, dislike of certain food, loss of appetite, weakness, palpitations of the heart, sensations of repletion, emesis, nausea, and heartburn was detected in the group receiving alizapride. Conclusion: While 5-HT3 antagonists are superior with respect to acute emesis, benzamides seem to be more efficient in the treatment of delayed emesis and are also less expensive in highly emetogenic cancer chemotherapy and highly emetogenic risk